Danish pharmaceutical company Bavarian Nordic is entering into a marketing and distribution agreement with Dynavac for the launch of a new hepatitis B vaccine in Germany, according to a press release published on Thursday.
Bavarian Nordic will market and distribute the Heplisav B vaccine for Dynavax. The companies expect it to be launched in the fourth quarter of 2021.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.